Does WellCare Cover Eliquis?

What Is Eliquis and Why Is Coverage So Important?

Eliquis (apixaban) is an oral anticoagulant approved by the FDA for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis and pulmonary embolism, and VTE prophylaxis after hip or knee replacement surgery [1]. Missing doses because of cost directly raises stroke and clotting risk. A 2019 analysis published in JAMA Internal Medicine found that cost-related non-adherence to anticoagulants was associated with a 46% higher rate of thromboembolic events over 12 months [2]. Insurance coverage, therefore, is not a minor financial question. It is a clinical one.

What Eliquis Is Prescribed For

The FDA label lists six approved indications [1]:

• Stroke and systemic embolism prevention in nonvalvular atrial fibrillation
• DVT treatment
• PE treatment
• DVT risk reduction following hip replacement
• DVT risk reduction following knee replacement
• Recurrent DVT and PE reduction following initial therapy

The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% relative to warfarin (hazard ratio 0.79; 95% CI 0.66 to 0.95; P<0.001) while also reducing major bleeding by 31% (hazard ratio 0.69; P<0.001) [3]. These outcomes are why physicians and the American Heart Association guidelines recommend apixaban as a first-line anticoagulant in eligible atrial fibrillation patients [4].

Why Formulary Placement Matters for Apixaban

Most Medicare Part D plans do cover Eliquis, but tier placement determines your actual cost. A Tier 3 drug on a WellCare Value Plus plan might cost $47 in the initial coverage phase, while the same drug on a WellCare Medicare Rx plan might sit at Tier 4 with a 25% coinsurance. Because apixaban is taken indefinitely in many patients, even a $30/month difference compounds to $360/year before accounting for coverage phase transitions.

How WellCare Part D Formularies Work

WellCare Health Plans, now part of Centene Corporation, offers both standalone Medicare Part D Prescription Drug Plans (PDPs) and Medicare Advantage Prescription Drug (MAPD) plans in most U.S. States. Each plan maintains its own formulary, updated annually each October 1 for the following benefit year.

Tier Structure on WellCare Plans

WellCare typically uses a 5-tier formulary:

| Tier | Drug Category | Typical Cost Share | |------|--------------|-------------------| | 1 | Preferred generics | $0, $5 copay | | 2 | Non-preferred generics | $10, $20 copay | | 3 | Preferred brands | $40, $55 copay | | 4 | Non-preferred brands | $80, $100+ or 25 to 33% coinsurance | | 5 | Specialty | 25 to 33% coinsurance |

Eliquis (brand) lands on Tier 3 or Tier 4 across most WellCare plans in 2025. Generic apixaban, introduced broadly in 2023 after Bristol-Myers Squibb's patent settlements, appears on Tier 1 or Tier 2 on many WellCare formularies, which can drop the 30-day cost to $5, $15.

Prior Authorization Requirements

WellCare requires prior authorization for brand Eliquis on most plans. The PA criteria typically confirm:

1. A covered diagnosis (AF, DVT, PE, or post-surgical VTE prophylaxis)
2. An FDA-approved dose
3. Documentation that the prescriber has evaluated renal function (since the 2.5 mg dose-reduction criteria depend on serum creatinine, weight, and age per the FDA label) [1]

Your prescriber submits PA documentation through WellCare's online portal or by fax. WellCare must respond to a standard PA request within 72 hours (or 24 hours for expedited requests, per CMS Part D regulations) [5].

Quantity Limits

Some WellCare plans cap Eliquis at a 30-day supply per fill or require step therapy (trying warfarin first for some indications). The American College of Chest Physicians 2022 guidelines recommend direct oral anticoagulants over vitamin K antagonists like warfarin for most patients with nonvalvular AF and VTE, citing superior net clinical benefit [6]. If your plan requires warfarin first, your physician can use this guideline evidence in a medical exception request.

How to Check Your Specific WellCare Plan's Eliquis Coverage

Coverage varies by plan year, state, and plan name. Do not rely on general statements. Take these steps to get an exact answer for your situation.

Step 1: Use the WellCare Formulary Search Tool

Go to WellCare.com, select your plan, and enter "apixaban" or "Eliquis" in the drug search. The tool shows tier, PA status, quantity limits, and your estimated cost at each pharmacy. Check both the brand name (Eliquis) and the generic (apixaban) because they may be on different tiers.

Step 2: Call WellCare Member Services

The number on the back of your member ID card connects you to a benefits specialist. Ask specifically:

• Is apixaban (generic) covered under my formulary?
• What tier is brand Eliquis on?
• Is prior authorization required?
• Does my plan have a step-therapy requirement?

Step 3: Check the Medicare Plan Finder

The CMS Medicare Plan Finder at medicare.gov allows you to enter your drugs and see estimated annual costs across all Part D plans in your zip code. This tool is updated with each plan's formulary data and is one of the most reliable ways to compare costs before open enrollment [5].

Step 4: Review the Annual Notice of Change

Each September, WellCare mails an Annual Notice of Change (ANOC) listing any formulary changes for the upcoming year. If Eliquis moves to a higher tier or gains new PA requirements, you have the right to switch plans during the October 15 to December 7 open enrollment window.

What Generic Apixaban Means for WellCare Patients

Generic apixaban became broadly available in the United States in 2023 following the expiration of exclusivity terms in Bristol-Myers Squibb's patent settlement agreements. This is the single most significant cost-reduction development for patients on this medication in over a decade.

Clinical Equivalence of Generic Apixaban

FDA bioequivalence standards require generics to deliver 80 to 125% of the reference drug's area under the curve (AUC) and peak concentration (Cmax), confirmed by in vivo pharmacokinetic studies [7]. The FDA's Office of Generic Drugs approved apixaban generics using these standards, meaning the active ingredient, dose, and absorption profile are therapeutically equivalent to brand Eliquis.

Cost Difference on WellCare Plans

On WellCare plans that have added generic apixaban to Tier 1 or Tier 2, a 30-day supply of 5 mg tablets may cost $5, $15 versus $47, $100 for the brand. Over a year, that difference can reach $400, $1,000, a meaningful sum for patients on fixed incomes.

Ask your pharmacist to dispense the generic unless your physician has specified "dispense as written" on the prescription. Many physicians write prescriptions for "apixaban" (the generic name) automatically, which allows substitution at the pharmacy level.

Prior Authorization: What Your Doctor Needs to Submit

Prior authorization denials are common for Eliquis on WellCare plans. Understanding what the PA requires helps your prescriber submit a complete packet on the first attempt, avoiding delays in coverage.

Typical PA Documentation Requirements

WellCare's PA criteria for apixaban generally ask for [5]:

• Diagnosis code (ICD-10: I48.x for AF; I82.x for DVT; I26.x for PE)
• Echocardiogram or ECG documentation for AF indication
• INR instability records if the patient was previously on warfarin
• Renal function labs (serum creatinine, eGFR) to justify dose
• Prescriber attestation that the dose matches FDA label criteria

Expedited PA for Urgent Situations

If a patient has just been diagnosed with a PE or AF and needs anticoagulation immediately, a 72-hour delay is clinically unacceptable. CMS regulations allow an expedited PA request when a standard 72-hour review would seriously jeopardize the enrollee's life or health [5]. Your physician documents this urgency, and WellCare must respond within 24 hours.

When PA Is Denied

A denial is not the end of the road. Patients have the right to request a coverage determination, then a redetermination, then an Independent Review Entity (IRE) review, then an ALJ hearing, and finally federal court review. This 5-level appeals process is guaranteed under CMS Part D regulations [5]. At the IRE level, an independent organization (currently Maximus Federal Services under CMS contract) reviews whether the denial was clinically justified. Studies examining Medicare Part D appeals have found that beneficiary-favorable decisions occur at IRE review in approximately 30 to 40% of cases where clinical documentation is complete [8].

How the 2025 Medicare Part D Changes Affect Eliquis Cost

The Inflation Reduction Act of 2022 restructured Part D benefits, with major changes phased in through 2025. These changes directly affect what WellCare patients pay for Eliquis.

The $2,000 Out-of-Pocket Cap

Starting in 2025, Medicare Part D has a $2,000 annual out-of-pocket cap [9]. Before this change, patients in the catastrophic phase still paid 5% coinsurance with no ceiling. For a patient paying $100/month for brand Eliquis, the cap limits total annual drug spending (across all Part D drugs) to $2,000 regardless of how high total drug costs climb.

The Medicare Prescription Payment Plan

CMS introduced the Medicare Prescription Payment Plan (M3P) in 2025, which allows beneficiaries to spread their out-of-pocket costs across monthly installments rather than paying large sums at the pharmacy counter in January [9]. This does not reduce total cost, but it eliminates the January "sticker shock" that causes many patients to skip fills at the start of the benefit year.

Low-Income Subsidy (Extra Help)

Medicare's Extra Help program (also called the Low-Income Subsidy) significantly reduces Part D costs for eligible beneficiaries. In 2025, full Extra Help beneficiaries pay no more than $11.20 per month for Tier 3 drugs like Eliquis [9]. Patients with income up to 150% of the federal poverty level may qualify. Applications go through the Social Security Administration at ssa.gov.

Alternatives to WellCare Coverage for Eliquis Cost

When WellCare's coverage results in unaffordable costs, several pathways exist.

Bristol-Myers Squibb Patient Assistance Program

Bristol-Myers Squibb offers the BMS Access Support program, which provides Eliquis at no cost to uninsured or underinsured patients who meet income criteria [10]. Eligibility generally requires household income below 400% of the federal poverty level and no adequate prescription coverage. Medicare beneficiaries whose Part D plan covers Eliquis are generally excluded from the manufacturer copay card, but the free drug program through BMS is available to Medicare patients who do not have Part D coverage for the drug.

NeedyMeds and RxAssist Databases

NeedyMeds.org and RxAssist.org maintain databases of patient assistance programs, state pharmaceutical programs, and copay foundations. The Patient Advocate Foundation Co-Pay Relief program, for instance, has historically offered grants specifically for cardiovascular drugs including anticoagulants, though funds are limited and program availability changes annually.

Switching to a Different Anticoagulant

Rivaroxaban (Xarelto) and dabigatran (Pradaxa) are also oral anticoagulants approved for AF and VTE. Their formulary placement on WellCare plans may differ. For AF, the RE-LY trial (N=18,113) showed dabigatran 150 mg reduced stroke by 34% relative to warfarin with similar major bleeding rates [11]. Rivaroxaban in the ROCKET-AF trial (N=14,264) demonstrated non-inferiority to warfarin for stroke prevention [12]. Neither is universally superior to apixaban across all outcomes, but if one agent sits at a lower tier on your WellCare plan, your cardiologist or hematologist can review whether a switch is medically appropriate. The American Heart Association/American College of Cardiology AF guidelines state that all four approved DOACs are reasonable choices for eligible patients [4].

Warfarin as a Step-Therapy Option

Warfarin (generic, Tier 1 on essentially all Part D plans) costs under $10/month. It requires regular INR monitoring, which adds its own time and cost burden. For patients with stable INR control, the net cost of warfarin plus monitoring may still be lower than brand Eliquis coinsurance. This is a clinical conversation between patient and prescriber, not a unilateral insurance decision.

Clinical Considerations: Who Must Not Switch Away From Apixaban

Not every patient can safely substitute a different anticoagulant. Forcing a switch purely for formulary reasons carries clinical risk in specific populations.

Mechanical Heart Valves

Apixaban and all DOACs are contraindicated in patients with mechanical heart valves. These patients require warfarin, so the coverage question does not apply [1].

Antiphospholipid Syndrome

The TRAPS trial (N=120) demonstrated that rivaroxaban was associated with significantly higher rates of thromboembolic events compared to warfarin in patients with triple-positive antiphospholipid syndrome [13]. The FDA subsequently issued safety communications advising against DOAC use in APS patients with triple positivity. If a WellCare plan denies Eliquis and recommends rivaroxaban or dabigatran, patients with antiphospholipid syndrome should have their physician document this contraindication in the PA appeal.

Severe Renal Impairment

All DOACs require dose adjustment or avoidance in severe renal impairment. Apixaban has the most favorable profile among DOACs at lower eGFR levels, and it is the only DOAC studied in end-stage renal disease. The AXADIA trial compared apixaban and phenprocoumon in dialysis patients with AF [14]. If a patient's cardiologist has selected apixaban specifically because of renal status, this rationale belongs in the PA documentation.

How to Appeal a WellCare Eliquis Denial

The five-level Medicare Part D appeals process gives patients meaningful recourse. Here is how each step works.

Level 1: Coverage Determination and Redetermination

After a denial, request a redetermination from WellCare within 60 days. WellCare reviews its own decision and must respond within 7 days (standard) or 72 hours (expedited) [5]. Win rate at this stage is lower because WellCare reviews its own denial.

Level 2: Independent Review Entity (IRE)

If WellCare upholds the denial, request IRE review. The IRE is a CMS-contracted independent organization. Submit clinical documentation: diagnosis records, echocardiogram, INR instability history, lab values, and a letter of medical necessity from your prescribing physician. The American Heart Association notes that when medical necessity is clearly documented, coverage denials for guideline-recommended therapies are frequently overturned at independent review [4].

Levels 3 to 5: ALJ, Medicare Appeals Council, Federal Court

These levels are available if the IRE upholds the denial, but most clinically supported cases resolve at Levels 1 to 2. An ALJ hearing is appropriate when the dollar amount at issue meets the annual threshold set by CMS (typically around $180 in 2025).

Letter of Medical Necessity: What Makes One Effective

A vague letter does not move PA committees. A strong letter of medical necessity for Eliquis on a WellCare plan includes:

• Patient's confirmed diagnosis with ICD-10 code
• CHA2DS2-VASc score if atrial fibrillation is the indication (score of 2+ in men, 3+ in women meets guideline threshold for anticoagulation per AHA/ACC) [4]
• HAS-BLED bleeding risk assessment
• Specific reason apixaban is preferred over alternatives (e.g., renal function, prior GI bleed on rivaroxaban, patient history of labile INR on warfarin)
• Reference to ARISTOTLE trial data showing apixaban's superiority over warfarin in both stroke prevention and major bleeding reduction [3]
• Statement that the prescribed dose matches FDA label criteria

The more specific the letter, the faster the approval or the stronger the appeal.